Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 17

705P - TIMES: A ctDNA tumor fraction based and externally validated nomogram to predict survival in cancer patients referred for early phase trials

Date

21 Oct 2023

Session

Poster session 17

Topics

Clinical Research;  Therapy

Tumour Site

Presenters

Antoine Italiano

Citation

Annals of Oncology (2023) 34 (suppl_2): S458-S497. 10.1016/S0923-7534(23)01936-1

Authors

A. Italiano1, L. Belcaid2, S. Cousin3, K. Trin4, A. Bayle5, I. Soubeyran6, M. Alamé7, L. Blouin8, E. Rouleau9, L. Lacroix10, D. Vasseur11, C. Bellera12

Author affiliations

  • 1 Early Phase Trials Unit, Institute Bergonié, 33000 - Bordeaux/FR
  • 2 Department Of Medical Oncology, Copenhagen University, 1017 - Copenhagen/DK
  • 3 Early Phase Trials, Institut Bergonie, 59020 - Bordeaux/FR
  • 4 Clinical Research, INSERM U1219 - Bordeaux Population Health - ISPED University of Bordeaux, 33076 - Bordeaux, Cedex/FR
  • 5 Ditep, Gustave Roussy, Paris/FR
  • 6 Biopathology, Institute Bergonié, 33076 - Bordeaux/FR
  • 7 Molecular Pathology, INSTITUT BERGONIE, 33000 - BORDEAUX/FR
  • 8 Molecular Pathologya, INSTITUT BERGONIE, 33800 - BORDEAUX/FR
  • 9 Tumor Genetics, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 10 Molecular Pathology, Institute Gustave Roussy, Paris/FR
  • 11 Molecular Biology, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 12 Clinical Research, institut bergonié, 33000 - Bordeaux/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 705P

Background

Typical entry criteria in early phase studies include expected life expectancy greater than 3 months. However, this evaluation is quite subjective and more objective and reproducible tools are needed to improve patient selection for phase I trials. The quantification of ctDNA shed by measuring tumor fraction (TF) has been associated with prognosis in patients with solid tumors. Our objective was to develop and validate a nomogram integrating TF to predict overall survival in cancer patients referred for early phase studies.

Methods

All consecutive adult patients with an advanced solid tumor included between December 2020 and December 2021 in two precision medicine studies (BIP, NCT02534649, sponsor: Institut Bergonié, Bordeaux, France) and STING (NCT04932525, sponsor: Institut Gustave Roussy, Villejuif, France). All patients underwent comprehensive genomic profiling with the 324-gene FoundationOne®. TF was analyzed as a binary variable, indicating whether a specimen had TF ≥10% or TF <10%. Other variables included previously validated prognostic scores such as the Royal Marsden (RMHs: albumin, LDH, number of metastatic sites ) and the GRIm (LDH, neutrophil/lymphocyte ratio, albumin) scores as well as their individual components.

Results

TF > 10, the GRIM score and the RMH score were independent prognostic factors in the training dataset (BIP study n= 965 patients). We generated a nomogram based on TF, number of metastatic sites, albumine level and neutrophil/lymphocyte ratio. To determine the clinical usefulness of our nomogram, we compared it with the RMH and GRIM scores. For our nomogram, the area under the receiver operating characteristic curve (AUC) was 0.79 as compared with 0.65 and 0.68 for the RMH and GRIM scores respectively. In the validation dataset (STING study, n= 947), the AUC was 0.76 as compared with 0.60 and 0.64 for for the RMH and GRIM scores respectively. The nomogram was well-calibrated in both the training and validation datasets.

Conclusions

This is the first prospective analysis confirming that TF is a strong prognostic factor in patients with advanced solid tumors. The TIMES nomogram represent an helpful tool in the process of patient selection for phase I trial entry.

Clinical trial identification

NCT02534649; NCT04932525.

Editorial acknowledgement

Legal entity responsible for the study

Institut Bergonié.

Funding

Fondation Bergonié, Fondation Gustave Roussy.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.